Floatz logo

Preladenant

Neoplasm

Merck Sharp & Dohme LLCSmall moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

928 Active assets in the Neoplasm cohort.

Asset / SponsorPhaseRating
PANITUMUMAB
Astellas Pharma Inc
Phase 2BBB
GRANULOCYTE COLONY-STIMULATING FACTOR LENOGRASTIM
Sanofi
Phase 4BB
Bxcl501
Medical College of Wisconsin
Phase 4BB
Relatlimab
Bristol-Myers Squibb
Phase 2BB
Vinorelbine
Shi Yanxia
Phase 3BB

View all 50 →

Same molecule, other indications

Preladenant is also rated in:

Parkinson diseaseDormant
B
Indicative ·
56 / 100
View asset →
central nervous system disorderDormant
CCC
Indicative ·
55 / 100
View asset →
neurodegenerative diseaseDormant
CCC
Indicative ·
55 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →